Session 100 - CROI 2007

Session 100 Poster Abstracts
Clinical Pharmacology of HIV Pis
Tuesday, 1 - 4 pm
Poster Hall

563	Effects of Tipranavir/Ritonavir on the Activity of Hepatic and Intestinal Cytochrome P450 3A4/5 and P-glycoprotein: Implications for Drug Interactions Manoli Vourvahis*¹, J Dumond¹, K Patterson¹, N Rezk¹, N White¹, S Jennings¹, H Tien¹, J Sabo², T MacGregor², and A Kashuba¹ ¹Univ of North Carolina at Chapel Hill, US and ²Boehringer Ingelheim Pharma, Ridgefield, CT, US
564	Drug-drug Interaction between Lopinavir/Ritonavir and Rosuvastatin D Hoody¹, Jennifer J. Kiser*², J Predhomme², D Flynn¹, and J Gerber² ¹Univ of Colorado Hosp, Denver, US and ²Univ of Colorado Hlth Sci Ctr, Denver, US
565	Assessment of Pharmacokinetic/Pharmacodynamic Relationships through 48 Weeks from a Study in HIV⁺, ART-naive Subjects Receiving Antiretroviral Regimens Containing Atazanavir 400 mg or Atazanavir/Ritonavir 300/100 mg Once Daily Richard Bertz*¹, Y Wang¹, L Mahnke¹, A Persson¹, E Chung¹, M Mathew², S Agarwala¹, D Filoramo¹, J Hammond², and D Grasela¹ ¹Bristol-Myers Squibb Pharma Res Inst, Princeton, NJ, US and ²Bristol-Myers Squibb Pharma Res Inst, Wallingford, CT, US
566	The Effect of Atazanavir and Atazanavir/Ritonavir on UGT1A4 Using Lamotrigine as a Phenotypic Probe David Burger^1,2, David Burger^1,2, A Huisman^1,2, A Huisman^1,2, N van Ewijk^1,2, N van Ewijk^1,2, H Neisingh¹, G Rongen¹, P Koopmans^1,2, P Koopmans^1,2, and R Bertz³ ¹Radboud Univ Med Ctr, Nijmegen, The Netherlands; ²Nijmegen Univ Ctr for Infectious Diseases, The Netherlands; and ³Bristol-Myers Squibb, Princeton, NJ, US
567	Effects of Minocycline and Valproic Acid Co-administration on Atazanavir Plasma Concentrations Robert DiCenzo^1,2, Robert DiCenzo^1,2, D Peterson¹, and G Schifitto¹ ¹Univ of Rochester, NY, US and ²Univ of Buffalo, NY, US
568	Effect of Famotidine 20- and 40-mg Dosing Regimens on the Bioavailability of Atazanavir with Ritonavir in Combination with Tenofovir in Healthy Subjects Sangeeta Agarwala*, A Persson, T Eley, M Child, D Filoramo, T Li, X Xu, and R Bertz Bristol-Myers Squibb Pharma Res Inst, Princeton, NJ, US